18 results on '"Bi, Rui"'
Search Results
2. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
- Author
-
Feng, Zheng, Shao, Di, Cai, Yuhang, Bi, Rui, Ju, Xingzhu, Chen, Dongju, Song, Chengcheng, Chen, Xiaojun, Li, Jin, An, Na, Li, Yunjin, Zhou, Qing, Xiu, Zhihui, Zhu, Shida, Wu, Xiaohua, and Wen, Hao
- Published
- 2023
- Full Text
- View/download PDF
3. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics
- Author
-
Cao, Bing, Sun, Chenbo, Bi, Rui, Liu, Zebing, Jia, Yijun, Cui, Wenli, Sun, Menghong, Yu, Baohua, Li, Xiaoqiu, and Zhou, Xiaoyan
- Published
- 2024
- Full Text
- View/download PDF
4. The abnormal expression of circ-ARAP2 promotes ESCC progression through regulating miR-761/FOXM1 axis-mediated stemness and the endothelial–mesenchymal transition
- Author
-
Xu, Pei, Wang, Lei, Liu, Qingtao, Gao, Pengkai, Hu, Fengqing, Xie, Xiao, Jiang, Lianyong, Bi, Rui, Ding, Fangbao, Yang, Qi, and Xiao, Haibo
- Published
- 2022
- Full Text
- View/download PDF
5. Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma
- Author
-
Ge, Huijuan, Xiao, Yaoxin, Qin, Guangqi, Gu, Yanzi, Cai, Xu, Jiang, Wenhua, Tu, Xiaoyu, Yang, Wentao, and Bi, Rui
- Published
- 2021
- Full Text
- View/download PDF
6. ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma
- Author
-
Bi, Rui, Bai, Qianming, Zhu, Xiaoli, Tu, Xiaoyu, Cai, Xu, Jiang, Wenhua, Xu, Xiaoli, Tang, Shaoxian, Ge, Huijuan, Chang, Bin, Cheng, Yufan, Gan, Hualei, Zhou, Xiaoyan, and Yang, Wentao
- Published
- 2019
- Full Text
- View/download PDF
7. Glial interleukin-1β upregulates neuronal sodium channel 1.7 in trigeminal ganglion contributing to temporomandibular joint inflammatory hypernociception in rats
- Author
-
Zhang, Peng, Bi, Rui-Yun, and Gan, Ye-Hua
- Published
- 2018
- Full Text
- View/download PDF
8. The preoperative prognostic nutritional index is a predictive and prognostic factor of high-grade serous ovarian cancer.
- Author
-
Feng, Zheng, Wen, Hao, Ju, Xingzhu, Bi, Rui, Chen, Xiaojun, Yang, Wentao, and Wu, Xiaohua
- Subjects
OVARIAN cancer ,NUTRITION ,SERUM albumin ,LYMPHOCYTE count ,KAPLAN-Meier estimator ,PROPORTIONAL hazards models ,CANCER risk factors ,TUMOR treatment ,NUTRITIONAL assessment ,OVARIAN tumors ,PROGNOSIS ,RESEARCH funding ,TUMORS ,TUMOR classification ,PREOPERATIVE period ,NUTRITIONAL status ,TUMOR grading - Abstract
Background: The aim of our study was to investigate whether an inflammation-based prognostic score, the prognostic nutritional index (PNI), was associated with clinical characteristics and prognosis in patients with high-grade serous ovarian cancer (HGSC).Methods: We retrospectively investigated 875 patients who underwent primary staging or debulking surgery for HGSC between April 2005 and June 2013 at our institution. None of these patients received neoadjuvant chemotherapy. Preoperative PNI was calculated as serum albumin (g/L) + 0.005 × lymphocyte count (per mm3). The optimal PNI cutoff value for overall survival (OS) was identified using the online tool "Cutoff Finder". Clinical characteristics and PNI were compared with chi-square or Fisher's exact tests, as appropriate. The impact of PNI on OS was analyzed using the Kaplan-Meier method and Cox proportional hazards model.Results: The median (range) PNI was 46.2 (29.2-67.7). The 45.45 cutoff value discriminated patients into the high-PNI and low-PNI groups. A low preoperative PNI was associated with an advanced FIGO stage, increased CA125 level, more extensive ascites, residual disease and platinum resistance. For univariate analyses, a high PNI was associated with increased OS (p < 0.001). In multivariate analyses, the PNI remained an independent predictor of OS as a continuous variable (p = 0.021) but not as dichotomized groups (p = 0.346).Conclusion: Our study demonstrated that the PNI could be a predictive and prognostic parameter for HGSC. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
9. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
- Author
-
Li, Ming, Li, Anqi, Zhou, Shuling, Xu, Yan, Xiao, Yaoxing, Bi, Rui, and Yang, Wentao
- Subjects
PROGRAMMED cell death 1 receptors ,PROTEIN expression ,LYMPHATIC metastasis ,BREAST cancer ,BIOMARKERS - Abstract
Background: Programmed cell death ligand 1 (PD-L1) is a potential predictive biomarker of the response to anti-PD-L1/anti- programmed cell death 1 (PD-1) therapy in multiple cancers, including triple negative breast cancer(TNBC). The purpose of this study was to investigate whether PD-L1 expression is homogenous in primary tumors(PTs) and synchronous axillary lymph node metastases(LNMs) of TNBC.Methods: PD-L1 expression was immunohistochemically evaluated in 101 TNBC patients' PTs and paired LNMs. PD-L1 expression in tumor cells and infiltrating immune cells or node lymphocytes in the PTs and associated LNMs was scored separately and was correlated with patients' clinical parameters and prognoses.Results: PD-L1 expression exhibited spatial heterogeneity in both the tumor cells and the infiltrating immune cells or node lymphocytes of PTs and LNMs. The PD-L1 expression levels were significantly higher in the lymphocytes and tumor cells of the LNMs than in the PTs. PD-L1 expression was also more frequent among the LNMs. PD-L1 expression was associated with high grade and more stromal tumor-infiltrating lymphocytes(TILs). Furthermore, the disease-free survival and overall survival were similar between the PT- negative/LNM- positive and PT- positive/LNM- positive patients, both of which exhibited worse disease-free survival(DFS) thanPT -negative/LNM -negative patients.Conclusions: The differential expression of PD-L1 between the PTs and LNMs suggests that LNMs PD-L1 status may be used to indicate whether PD-1/PD-L1-targeted therapy would be suitable for a node-positive TNBC patient in the future. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
10. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
- Author
-
Zheng Feng, Hao Wen, Rui Bi, Yachen Duan, Wentao Yang, Xiaohua Wu, Feng, Zheng, Wen, Hao, Bi, Rui, Duan, Yachen, Yang, Wentao, and Wu, Xiaohua
- Subjects
OVARIAN cancer patients ,HEALTH outcome assessment ,FIBRINOGEN ,OVARIAN cancer ,CHEMORECEPTORS ,PROGNOSIS ,TUMOR surgery ,MEMBRANE proteins ,OVARIAN tumors ,THROMBOCYTOSIS ,TUMOR antigens ,TUMORS ,RETROSPECTIVE studies ,PLATELET count - Abstract
Background: Over 20% of ovarian cancer patients have preoperative thrombocytosis or hyperfibrinogenemia. We aimed to demonstrate the clinical and prognostic significance of thrombocytosis and hyperfibrinogenemia in high-grade serous ovarian cancer (HGSC).Methods: We retrospectively investigated HGSC patients who underwent primary staging or debulking surgery between April 2005 and June 2013 in our institution. None of these patients had received neoadjuvant chemotherapy. Data, including age, performance status, FIGO stage, serum CA125, platelet count, fibrinogen level, and surgical residual disease, were collected. Thrombocytosis was defined as a platelet count greater than 450 × 10(9)/L, and hyperfibrinogenemia was defined as a fibrinogen level higher than 4.00 g/L. Progression-free survival (PFS) and overall survival (OS) were analyzed with the Kaplan-Meier method and log-rank tests for univariate analyses. For the multivariate analyses, Cox regression analysis was used to evaluate the effects of the prognostic factors, which are expressed as hazard ratios (HRs).Results: A total of 875 consecutive HGSC patients were identified. The median follow-up time was 29 (1-115) months. The median (interquartile range, IQR) preoperative platelet count was 301 (235-383) × 10(9)/L, and 121 (13.8%) women had thrombocytosis. The median (IQR) preoperative fibrinogen level was 3.85 (3.19-4.45) g/L, and 332 (45.9%) of the patients had hyperfibrinogenemia. Both preoperative thrombocytosis and hyperfibrinogenemia were associated with an advanced FIGO stage (p = 0.008 and <0.001, respectively), an increased CA125 level (p = 0.004 and 0.001, respectively), more extensive ascites (p < 0.001 and <0.001, respectively), more extensive residual disease (p < 0.001 and <0.001, respectively) and chemosensitivity (p = 0.043 and <0.001, respectively). In the univariate analyses, hyperfibrinogenemia was associated with reduced PFS (p < 0.001) and OS (p < 0.001). However, thrombocytosis was not found to be a potential predictor of PFS (P = 0.098) or OS (p = 0.894). In the multivariate analyses, hyperfibrinogenemia was an independent predictor of OS (p = 0.014) but not PFS (p = 0.062).Conclusion: Preoperative thrombocytosis and hyperfibrinogenemia reflected tumor burden to some extent and thus influenced treatment outcomes, and the fibrinogen level was found to be useful as a prognostic predictor in the HGSC patients. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
11. Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma.
- Author
-
Cui, Wenli, Cai, Ying, Wang, Weige, Liu, Zebing, Wei, Ping, Bi, Rui, Chen, Weixiang, Sun, Menghong, and Zhou, Xiaoyan
- Abstract
Background: It has been reported that the PI3K/AKT signaling pathway is activated in diffuse large B-cell lymphoma (DLBCL), PI3K constitutive activation plays a crucial role in PI3K/AKT pathway. However, the copy number variations (CNVs) of PI3K subunits on gene level remain unknown in DLBCL. Therefore, the aim of the study is to investigate the CNV of PI3K subunits and their relationship with clinicopathological features exploring the possible mechanism underlying of PI3K activation in DLBCL.Methods: CNV of 12 genes in the PI3K/AKT pathway was detected by NanoString nCounter in 60 de novo DLBCLs and 10 reactive hyperplasia specimens as controls. Meanwhile, immunohistochemistry (IHC) was performed to examine the expression of p110α, p110β, p110γ, p110δ, and pAKT on DLBCL tissue microarrays.Results: All PI3K and AKT subunits, except for PIK3R1, had various CNVs in the form of copy number amplifications and copy number losses. Their rates were in the range of 8.3-20.0%. Of them PIK3CA and PIK3CB gene CNVs were significantly associated with decreased overall survival (P = 0.029 and P = 0.019, respectively). IHC showed that the frequency of strong positive expression of p110α, p110β, p110γ, and p110δ were 26.7%, 25.0%, 18.3%, and 25.0% respectively, and they were found to be associated with decreased survival (P = 0.022, P = 0.015, P = 0.015, and P = 0.008, respectively). Expression of p110α was not only significantly associated with CNVs of PIK3CA (P = 0.002) but also positively correlated with strong positive expression of pAKT (P = 0.026).Conclusions: CNV of PIK3CA is highly associated with aberrant p110α protein expression and subsequent activation of PI3K/AKT pathway. CNVs of PIK3CA and PIK3CB, and aberrant protein expression of p110 isoforms are of great important value for predicting inferior prognosis in DLBCL. Frequent CNVs of PI3K/AKT subunits may play an important role in the tumorigenesis of DLBCL. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
12. Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary.
- Author
-
Xu Y, Bi R, Xiao Y, Tu X, Li M, Li A, Shan L, Zhou S, and Yang W
- Subjects
- Adult, Aged, Asian People genetics, Cystadenocarcinoma, Serous mortality, Cystadenocarcinoma, Serous pathology, DNA Mutational Analysis, Disease-Free Survival, Female, Humans, Middle Aged, Mutation, Neoplasm Grading, Ovarian Neoplasms mortality, Ovarian Neoplasms pathology, Prognosis, Young Adult, Cystadenocarcinoma, Serous genetics, Ovarian Neoplasms genetics, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins p21(ras) genetics
- Abstract
Background: Mounting evidence has shown that KRAS and BRAF are somatic mutations associated with low grade serous carcinoma (LGSC) of the ovary. However, the frequency of KRAS or BRAF mutation was variable in literatures, with a frequency of 16-54% for KRAS mutation and 2-33% for BRAF mutation. Meanwhile, the prognostic significance of KRAS or BRAF mutation remains controversial., Methods: Codons 12 and 13 of exon 2 of KRAS gene and exon 15 of BRAF gene were analyzed using direct Sanger sequencing in 32 cases of LGSC of the ovary. The associations between KRAS or BRAF mutation and clinicopathological characteristics, overall survival (OS) and disease-free survival (DFS) were statistically analyzed., Results: KRAS mutation was observed in nine cases (9/32, 28%) and BRAF mutation in two cases (2/32, 6%). KRAS and BRAF mutations were mutually exclusive. Neither KRAS nor BRAF mutation was statistically associated with OS or DFS in our cohort, although there was a favorable prognostic trend in patients with KRAS G12D mutation than those with KRAS G12 V mutation or wild-type KRAS for OS., Conclusions: The present study indicated a low frequency of BRAF or KRAS mutation in Chinese patients with LGSC of the ovary, and neither KRAS nor BRAF mutation is a prognostic factor.
- Published
- 2017
- Full Text
- View/download PDF
13. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
- Author
-
Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S, and Cheng X
- Subjects
- Adenocarcinoma, Clear Cell diagnosis, Adenocarcinoma, Clear Cell mortality, Adult, Aged, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cohort Studies, Female, Humans, Immunohistochemistry, Middle Aged, Neoplasm Grading, Neoplasm Staging, Ovarian Neoplasms diagnosis, Tissue Array Analysis, Treatment Outcome, Adenocarcinoma, Clear Cell drug therapy, Adenocarcinoma, Clear Cell metabolism, Antineoplastic Agents therapeutic use, Biomarkers, Tumor, Molecular Targeted Therapy, Ovarian Neoplasms drug therapy, Ovarian Neoplasms metabolism, Precision Medicine
- Abstract
Background: It has long been appreciated that different subtypes (serous, clear cell, endometrioid and mucinous) of epithelial ovarian carcinoma (EOC) have distinct pathogenetic pathways. However, clinical management, especially chemotherapeutic regimens, for EOC patients is not subtype specific. Ovarian clear cell carcinoma (CCC) is a rare histological subtype of EOC, which exhibits high rates of recurrence and low chemosensitivity. We assessed potential therapeutic targets for ovarian CCC patients through analyzing the variation of drug-based molecular biomarkers expression between ovarian CCC and high-grade serous carcinoma (HGSC)., Methods: Seven candidate drug-based molecular biomarkers, human epidermal growth factor receptor (EGFR), human epidermal growth factor receptor-2 (HER2), phosphatase and tensin homolog deleted on chromosome ten (PTEN), aurora kinase A (AURKA), breast cancer susceptibility gene 1 (BRCA1), breast cancer susceptibility gene 2 (BRCA2) and programmed death-ligand 1 (PD-L1) were measured in 96 ovarian CCC and 113 HGSC by immunohistochemistry in paraffin embedded tissues. The relationship between these biomarkers and clinicopathological factors were explored., Results: The expression level of four of the seven drug-based molecular biomarkers was markedly different between HGSC and CCC. High expression levels of HER2 and PD-L1 were more commonly observed in CCC patients (12.6% vs 2.7%, 21.1% vs 11.6%, P = 0.006, 0.064, respectively), while loss of BRCA1 and BRCA2 expression were more frequently occurred in HGSC patients (72.6% vs 54.3%, 89.4% vs 79.8%, P = 0.007, 0.054, respectively). Survival analysis showed that five of seven biomarkers had prognostic values but varied between subtypes. Furthermore, EGFR expressed frequently in CCC patients with endometriosis than in HGSC patients (44.4% vs 8.3%, P = 0.049). AURKA and PD-L1 correlated with the resistance to platinum-based chemotherapy in CCC patients (P = 0.043, 0.028, respectively) while no similar results were observed in HGSC patients., Conclusion: Ovarian CCC showed a markedly different expression map of drug-based molecular biomarkers from HGSC, which suggested a new personalized target therapy in this rare subtype.
- Published
- 2017
- Full Text
- View/download PDF
14. Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).
- Author
-
Feng Z, Wen H, Ju X, Bi R, Chen X, Yang W, and Wu X
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Cystadenocarcinoma, Serous drug therapy, Cystadenocarcinoma, Serous mortality, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Neoplasm Staging, Ovarian Neoplasms drug therapy, Ovarian Neoplasms mortality, Prognosis, Retrospective Studies, Treatment Outcome, Cystadenocarcinoma, Serous metabolism, Cystadenocarcinoma, Serous pathology, Gonads metabolism, Hormones metabolism, Hypothalamus metabolism, Ovarian Neoplasms metabolism, Ovarian Neoplasms pathology, Pituitary Gland metabolism, Receptors, Cell Surface metabolism
- Abstract
Background: The aim of our study was to investigate the clinical features and expression levels of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)., Methods: We retrospectively investigated the clinical features of 26 consecutive patients with LGSC who underwent primary staging or debulking surgery between April 2005 and June 2013 in our center; concomitant primary high-grade serous ovarian cancer (HGSC) patients were randomly selected at a 2:1 ratio for comparison. Tissue microarrays were constructed from the LGSC and HGSC specimens, and the expression levels of six hormone receptors in the hypothalamic pituitary-gonadal axis were analyzed by immunohistochemistry., Results: The median (range) age of patients with LGSC was 54 (27-77) years. According to the FIGO staging system, the cases were distributed as follows: stage I, 6 (23.1%); stage II, 0 (0%); stage III, 19 (73.1%); and stage IV, 1 (3.8%). The 2-year and 5-year overall survival rates for LGSC were 91.8% and 67.5%, respectively. The expression levels of the hormone receptors were as follows: ER, 80.8%; PR, 34.6%; AR, 53.8%; FSHR, 84.0%; LHR, 65.4%; and GnRHR, 100%. Hormone receptor-positive patients had a better prognosis compared with hormone receptor-negative patients, but the difference was not significant., Conclusions: Our study presented a higher overall survival rate and distinctive hormone receptor expression levels of LGSC patients compared with the HGSC cohort. Patients with positive hormone receptor expression tended to have a better prognosis than the corresponding hormone receptor negative patients.
- Published
- 2017
- Full Text
- View/download PDF
15. Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression.
- Author
-
Bi R, Shen X, Zhang W, Cheng Y, Feng Z, Cai X, and Yang W
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma mortality, Carcinoma pathology, Carcinoma therapy, Carcinoma, Ovarian Epithelial, China, Disease-Free Survival, Female, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Middle Aged, Neoplasm Staging, Neoplasms, Glandular and Epithelial mortality, Neoplasms, Glandular and Epithelial pathology, Neoplasms, Glandular and Epithelial therapy, Ovarian Neoplasms mortality, Ovarian Neoplasms pathology, Ovarian Neoplasms therapy, Risk Factors, Time Factors, Treatment Outcome, Young Adult, Biomarkers, Tumor analysis, Carcinoma chemistry, Neoplasms, Glandular and Epithelial chemistry, Ovarian Neoplasms chemistry, RNA-Binding Proteins analysis
- Abstract
Background: Ovarian clear cell carcinoma (CCC) is an uncommon subtype of ovarian epithelial tumor. The prognostic significance of its clinicopathological parameters is discordant, with the exception of stage as the adverse prognostic factor. The present study aimed to evaluate the prognostic significance of its clinicopathological characteristics and the expression of IMP3 (Insulin-like growth factor-II mRNA-binding protein 3, IMP3 or IGF2BP3) in Chinese patients with primary pure CCC., Methods: We collected clinicopathological data from 73 cases with a minimum of 5 years of follow-up and evaluated the expression of IMP3 by immunohistochemistry., Results: In total, 49.3 % of the patients were in stage I. Advanced stages were closely related to poor prognosis of disease-free survival (DFS) and overall survival (OS) (P < 0.005). Patients with CCC coexisting with endometriosis tended to be younger and to have unilateral involvement but did not exhibit differences in prognosis compared with patients with CCC without endometriosis. Other histological features such as growth pattern, mitosis, and necrosis did not have prognostic significance. IMP3 was positive in 63 % of patients (46 of 73 cases); Thus, positive expression of IMP3 is an adverse prognostic marker in terms of OS (P = 0.012), even in stage I patients (P = 0.038)., Conclusions: The present study demonstrates that IMP3 expression is a prognostic marker, with the exception of stage. IMP3 represents a biomarker of unfavorable prognosis even in stage I patients.
- Published
- 2016
- Full Text
- View/download PDF
16. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
- Author
-
Feng Z, Wen H, Bi R, Duan Y, Yang W, and Wu X
- Subjects
- Adult, Aged, CA-125 Antigen blood, Cystadenocarcinoma, Serous pathology, Cystadenocarcinoma, Serous surgery, Disease-Free Survival, Female, Humans, Membrane Proteins blood, Middle Aged, Ovarian Neoplasms pathology, Ovarian Neoplasms surgery, Platelet Count, Retrospective Studies, Thrombocytosis pathology, Cystadenocarcinoma, Serous blood, Fibrinogen metabolism, Ovarian Neoplasms blood, Prognosis, Thrombocytosis blood
- Abstract
Background: Over 20% of ovarian cancer patients have preoperative thrombocytosis or hyperfibrinogenemia. We aimed to demonstrate the clinical and prognostic significance of thrombocytosis and hyperfibrinogenemia in high-grade serous ovarian cancer (HGSC)., Methods: We retrospectively investigated HGSC patients who underwent primary staging or debulking surgery between April 2005 and June 2013 in our institution. None of these patients had received neoadjuvant chemotherapy. Data, including age, performance status, FIGO stage, serum CA125, platelet count, fibrinogen level, and surgical residual disease, were collected. Thrombocytosis was defined as a platelet count greater than 450 × 10(9)/L, and hyperfibrinogenemia was defined as a fibrinogen level higher than 4.00 g/L. Progression-free survival (PFS) and overall survival (OS) were analyzed with the Kaplan-Meier method and log-rank tests for univariate analyses. For the multivariate analyses, Cox regression analysis was used to evaluate the effects of the prognostic factors, which are expressed as hazard ratios (HRs)., Results: A total of 875 consecutive HGSC patients were identified. The median follow-up time was 29 (1-115) months. The median (interquartile range, IQR) preoperative platelet count was 301 (235-383) × 10(9)/L, and 121 (13.8%) women had thrombocytosis. The median (IQR) preoperative fibrinogen level was 3.85 (3.19-4.45) g/L, and 332 (45.9%) of the patients had hyperfibrinogenemia. Both preoperative thrombocytosis and hyperfibrinogenemia were associated with an advanced FIGO stage (p = 0.008 and <0.001, respectively), an increased CA125 level (p = 0.004 and 0.001, respectively), more extensive ascites (p < 0.001 and <0.001, respectively), more extensive residual disease (p < 0.001 and <0.001, respectively) and chemosensitivity (p = 0.043 and <0.001, respectively). In the univariate analyses, hyperfibrinogenemia was associated with reduced PFS (p < 0.001) and OS (p < 0.001). However, thrombocytosis was not found to be a potential predictor of PFS (P = 0.098) or OS (p = 0.894). In the multivariate analyses, hyperfibrinogenemia was an independent predictor of OS (p = 0.014) but not PFS (p = 0.062)., Conclusion: Preoperative thrombocytosis and hyperfibrinogenemia reflected tumor burden to some extent and thus influenced treatment outcomes, and the fibrinogen level was found to be useful as a prognostic predictor in the HGSC patients.
- Published
- 2016
- Full Text
- View/download PDF
17. Malignant ameloblastoma (metastatic ameloblastoma) in the lung: 3 cases of misdiagnosis as primary lung tumor with a unique growth pattern.
- Author
-
Bi R, Shen L, Zhu X, and Xu X
- Subjects
- Adult, Ameloblastoma secondary, Biomarkers, Tumor analysis, Female, Humans, Immunohistochemistry, Jaw Neoplasms pathology, Lung Neoplasms secondary, Middle Aged, Multimodal Imaging, Ameloblastoma diagnosis, Diagnostic Errors, Lung Neoplasms diagnosis
- Abstract
Malignant ameloblastoma (metastatic ameloblastoma, MA) is currently defined as a distinct pathologic entity, MA, despite its histologically benign appearance. According to the new criteria, the histological and clinical features of MA are more homogenous. Here, we report three cases of histologically confirmed pulmonary MA. Two of the three patients complained of chest pain as the primary symptom, and the other case was detected upon the evaluation of pulmonary nodules found during a health examination after a local recurrence of mandible ameloblastoma. All three patients were female with an average age of 48 years. The intervals between the primary ameloblastoma and metastasis to the lung were 14 years, 19 years and 10 years, averaging 14.3 years. Prior to metastasis to the lung, only one patient experienced local recurrences, at 5 and 19 years after the primary tumor resection, while the other two patients both remained disease-free. Computed tomography (CT) or X-ray evaluation demonstrated multiple bilateral lung nodules ranging in size from several millimeters up to 2 cm. Histologically, the pulmonary metastatic tumors showed a unique growth pattern: the tumor cells grew among the interstitial alveoli but did not appear to destructively infiltrate the surrounding tissue. Immunohistochemically, the MA cells expressed squamous differentiation markers, such as CK10/13 and p63, while the alveolar epithelial cells stained for TTF1 and PE10. In this paper, we discuss the clinical behavior, differential diagnosis and unique growth pattern of pulmonary MA.
- Published
- 2015
- Full Text
- View/download PDF
18. The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms.
- Author
-
Cai Y, Cui W, Chen W, Wei P, Chi Y, Zhang P, Bi R, and Zhou X
- Abstract
Background: Epigenetic control using histone deacetylase (HDAC) inhibitors is a promising therapy for lymphomas. Insights into the anti-proliferative effects of HDAC inhibitors on diffuse large B-cell lymphoma (DLBCL) and further understanding of the underlying mechanisms, which remain unclear to date, are of great importance., Methods: Three DLBCL cell lines (DoHH2, LY1 and LY8) were used to define the potential epigenetic targets for Trichostatin A (TSA)-mediated anti-proliferative effects via CCK-8 assay. Cell cycle distribution and apoptosis were detected by flow cytometry. We further investigated the underlying molecular mechanisms by examining expression levels of relevant proteins using western blot analysis., Results: TSA treatment inhibited the growth of all three DLBCL cell lines and enhanced cell cycle arrest and apoptosis. Molecular analysis revealed upregulated acetylation of histone H3, α-tubulin and p53, and dephosphorylation of pAkt with altered expression of its main downstream effectors (p21, p27, cyclin D1 and Bcl-2). HDAC profiling revealed that all three cell lines had varying HDAC1-6 expression levels, with the highest expression of all six isoforms, in DoHH2 cells, which displayed the highest sensitivity to TSA., Conclusion: Our results demonstrated that the HDAC inhibitor TSA inhibited DLBCL cell growth, and that cell lines with higher expression of HDACs tended to be more sensitive to TSA. Our data also suggested that inhibition of pAkt and activation of p53 pathway are the main molecular events involved in inhibitory effects of TSA.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.